Treatment duration of obsessive compulsive disorder

Area of Science:

• Psychiatry
• Pharmacology
• Neuroscience

Background:

• Obsessive-compulsive disorder (OCD) treatment has evolved significantly since the 1967 report on clomipramine (CMI).
• Early studies highlighted CMI's efficacy, with controlled trials emerging in the 1980s and large-scale studies in the 1990s.
• The selective effectiveness of CMI among tricyclic antidepressants (TCAs) led to the serotonergic hypothesis of OCD.

Purpose of the Study:

• To review existing data on treatment duration for obsessive-compulsive disorder (OCD).
• To explore the pharmacological approaches to OCD, focusing on serotonergic agents.
• To consolidate current knowledge on the timeline of OCD treatment.

Main Methods:

• Literature review of published studies on clomipramine (CMI) and other serotonergic agents for OCD.
• Analysis of controlled trials and large-scale studies investigating antidepressant efficacy in OCD.
• Examination of data pertaining to treatment duration in OCD.

Main Results:

• Clomipramine (CMI) is the only tricyclic antidepressant (TCA) demonstrating efficacy in OCD treatment.
• Antidepressants with a noradrenergic profile, such as desipramine (DMI), are ineffective for OCD.
• Several serotonergic drugs, including fluoxetine, fluvoxamine, sertraline, paroxetine, and citalopram, are under investigation for OCD.

Conclusions:

• The serotonergic hypothesis of OCD is supported by the selective efficacy of CMI.
• Further research is needed to establish optimal treatment durations for OCD.
• The field is advancing with the development and study of various serotonergic agents for OCD management.